Nautilus Biotechnology Inc. has announced the launch of its Early Access Program for a novel single-molecule proteomics platform, starting with a validated tau proteoforms assay. This program provides select researchers exclusive access to Nautilus' Iterative Mapping method, with the aim of accelerating Alzheimer's and neurodegenerative disease research. The company will highlight the quantitative benefits of its Iterative Mapping technology and present updated data from its research collaboration with the Buck Institute during an upcoming webinar scheduled for January 14, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nautilus Biotechnology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9622033-en) on January 08, 2026, and is solely responsible for the information contained therein.